Kimberly McBennett, MD
Pediatric Pulmonology · Cleveland, OHNPI 1144205592
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,038 of the $7,563 with a category attached, or 79.8%. Vertex accounts for 95.3% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2020 at $4,514 and has fallen 98.2% since, to $82 in 2025.
Across 32 payments — averaging $236.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$7K
- AbbVie$86
- Aimmune Therapeutics, Inc.$71
- Digestive Care, Inc.$68
- Nestle Healthcare Nutrition Inc.$44
- Chiesi USA, Inc.$32
- plus $53 from 2 others
Across 47 payments — averaging $13,269 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$372K
- Vertex$250K
- Vivus LLC$2K
What the payments were for
- Consulting fees$6,03880%
- Travel & lodging$95813%
- Food & beverage$5367%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 13 | $7,209 |
| AbbVie(2 entities) | 5 | $86 |
| Aimmune Therapeutics, Inc. | 4 | $71 |
| Digestive Care, Inc. | 3 | $68 |
| Nestle Healthcare Nutrition Inc. | 2 | $44 |
| Chiesi USA, Inc. | 2 | $32 |
| Gilead | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRIKAFTA$4,233
How this compares
$7,563 in reported general payments places this provider in the 85th percentile of 68 pediatric pulmonology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 189 | $4,956,226 |
| KalydecoIvacaftor | 24 | $638,921 |
| CaystonAztreonam Lysine | 40 | $466,772 |
| ZenpepLipase/Protease/Amylase | 31 | $233,566 |
| PertzyeLipase/Protease/Amylase | 34 | $188,235 |
| CreonLipase/Protease/Amylase | 35 | $164,857 |
| ColistimethateColistin (Colistimethate Na) | 30 | $20,830 |
| EliquisApixaban | 16 | $17,629 |
| Advair HfaFluticasone Propion/Salmeterol | 47 | $17,266 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $9,647 |
| LinzessLinaclotide | 13 | $6,953 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 89 | $2,873 |
| Ursodiol | 20 | $2,024 |
| Vancomycin Hcl | 11 | $1,968 |
| Ventolin HfaAlbuterol Sulfate | 20 | $1,439 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| VertexTrikafta, Kalydeco | $7,209 | $5,595,148213 claims |
| GileadCayston | $31 | $466,77240 claims |
| Aimmune Therapeutics, Inc.Zenpep | $71 | $233,56631 claims |
| Digestive Care, Inc.Pertzye | $68 | $188,23534 claims |
| AbbVieCreon, Linzess | $86 | $171,80948 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 68 pediatric pulmonology providers in Ohio.
Other pediatric pulmonology in Cleveland
- Michael KonstanCleveland$84K
- Erica RoeschCleveland$13K
- John CarlCleveland$491
- Amy DimarinoCleveland$411
- Daniel CravenCleveland$403
- Silvia Cardenas ZegarraCleveland$298
- Robert SternCleveland$42
- Pamela DavisCleveland$38
- Parevi MajmudarCleveland$31
- Carol RosenCleveland$31
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.